From the Journals

Aerosolized MMR vaccine showed good seropositivity

Publish date: May 12, 2017
By
Catherine Cooper Nellist

 

FROM VACCINE

Aerosolized MMR vaccine can be used in booster campaigns in school-age children for measles and rubella, said José Luis Díaz Ortega, MD, of the Instituto Nacional de Salud Pública, Mexico, and his associates.

However, more studies of school-age children with longer follow-up of mumps antibody persistence are needed, they said.

CDC/ Cynthia S. Goldsmith; William Bellini, Ph.D.

Measles viron

A 1-year serological follow-up study was done in 241 Mexican children aged 6-7 years who received vaccine MMR SII (Serum Institute of India) administered by aerosol or injection or MMR II (Merck Sharp & Dohme) by aerosol or injection. The children had a history of receiving MMR at age 1-2 years. The aerosolization was performed through a vibrating mesh nebulizer.

Courtesy CDC/NIP/Barbara Rice

Measles cases has reached a 20-year high in the United States, with 288 reported as of May 23.

The persistence of immunity 1 year after the booster vaccination showed 100% seropositivity for measles and rubella and 90.3%-96.6% for mumps. The differences were not statistically significant among the four groups (P = .485).

Aerosolized vaccines are not available in the United States.

Read more in the journal Vaccine (2017 Apr 28. doi: 10.1016/j.vaccine.2017.04.027).

Next Article:

Two-dose HPV vaccine trials in teens show effective immunological responses